https://www.selleckchem.com/products/gsk503.html
ect younger male populations from unintended harms. Sentinel lymph node (SLN) mapping agents approved for current surgical practice lack sufficient brightness and target specificity for high-contrast, sensitive nodal visualization. To evaluate whether an ultrasmall, molecularly targeted core-shell silica nanoparticle (Cornell prime dots) can safely and reliably identify optically avid SLNs in head and neck melanoma during fluorescence-guided biopsy. This nonrandomized clinical trial enrolled patients aged 18 years or older with histologi